CL2017000866A1 - Compuestos y composiciones para el tratamiento o prevencion de trastornos patologicos asociados con exceso de deposicion de fibrina y/o formacion de trombos - Google Patents

Compuestos y composiciones para el tratamiento o prevencion de trastornos patologicos asociados con exceso de deposicion de fibrina y/o formacion de trombos

Info

Publication number
CL2017000866A1
CL2017000866A1 CL2017000866A CL2017000866A CL2017000866A1 CL 2017000866 A1 CL2017000866 A1 CL 2017000866A1 CL 2017000866 A CL2017000866 A CL 2017000866A CL 2017000866 A CL2017000866 A CL 2017000866A CL 2017000866 A1 CL2017000866 A1 CL 2017000866A1
Authority
CL
Chile
Prior art keywords
prevention
treatment
fibrin
compositions
compounds
Prior art date
Application number
CL2017000866A
Other languages
English (en)
Inventor
Sverker Jern
Jonas Faijerson Saeljoe
Niklas Bergh
Original Assignee
Cereno Scient Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cereno Scient Ab filed Critical Cereno Scient Ab
Publication of CL2017000866A1 publication Critical patent/CL2017000866A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

<p>LA PRESENTE INVENCIÓN PROPORCIONA ÁCIDO VALPROICO O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DEL MISMO, PARA UTILIZARSE EN EL TRATAMIENTO O PREVENCIÓN DE UN TRASTORNO PATOLÓGICO ASOCIADO CON UN EXCESO DE DEPOSICIÓN DE FIBRINA Y/O FORMACIÓN DE TROMBOS, EN DONDE EL TRATAMIENTO COMPRENDE TRATAR A UN PACIENTE CON ÁCIDO VALPROICO O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DEL MISMO, DE UNA MANERA ESPECÍFICA, Y FORMULACIONES PARA USARSE O DISEÑADAS PARA USARSE EN TALES TRATAMIENTOS.</p>
CL2017000866A 2014-10-08 2017-04-07 Compuestos y composiciones para el tratamiento o prevencion de trastornos patologicos asociados con exceso de deposicion de fibrina y/o formacion de trombos CL2017000866A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1417828.9A GB201417828D0 (en) 2014-10-08 2014-10-08 New methods and compositions

Publications (1)

Publication Number Publication Date
CL2017000866A1 true CL2017000866A1 (es) 2017-11-24

Family

ID=51947070

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017000866A CL2017000866A1 (es) 2014-10-08 2017-04-07 Compuestos y composiciones para el tratamiento o prevencion de trastornos patologicos asociados con exceso de deposicion de fibrina y/o formacion de trombos

Country Status (20)

Country Link
US (4) US10111845B2 (es)
EP (2) EP4066825A1 (es)
JP (2) JP6787901B2 (es)
KR (2) KR20250005512A (es)
CN (3) CN115721635A (es)
AU (1) AU2015329795B2 (es)
BR (1) BR112017007144A2 (es)
CA (2) CA2964041C (es)
CL (1) CL2017000866A1 (es)
DK (1) DK3203997T3 (es)
ES (1) ES2913225T3 (es)
GB (1) GB201417828D0 (es)
HU (1) HUE058316T2 (es)
IL (1) IL251142B (es)
MX (2) MX2017004558A (es)
MY (1) MY192055A (es)
PL (1) PL3203997T3 (es)
RU (1) RU2732761C2 (es)
SG (1) SG11201702058XA (es)
WO (1) WO2016055797A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
JP6602779B2 (ja) 2014-02-13 2019-11-06 インサイト・コーポレイション Ｌｓｄ１阻害剤としてのシクロプロピルアミン類
EP3105218B1 (en) 2014-02-13 2019-09-25 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
US9695180B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
WO2016007731A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyridines and imidazopyrazines as lsd1 inhibitors
GB201417828D0 (en) 2014-10-08 2014-11-19 Cereno Scient Ab New methods and compositions
EP3277689B1 (en) 2015-04-03 2019-09-04 Incyte Corporation Heterocyclic compounds as lsd1 inhibitors
MY189367A (en) 2015-08-12 2022-02-08 Incyte Corp Salts of an lsd1 inhibitor
WO2017175010A1 (en) * 2016-04-08 2017-10-12 Cereno Scientific Ab Compounds and compositions for the treatment or prevention of pathological conditions associated with excess fibrin deposition and/or thrombus formation
CA3018043A1 (en) 2016-04-08 2017-10-12 Cereno Scientific Ab Delayed release pharmaceutical formulations comprising valproic acid, and uses thereof
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
WO2021146257A1 (en) * 2020-01-16 2021-07-22 The Regents Of The University Of Michigan Concentrated sodium valproate for rapid delivery
CN111450072B (zh) * 2020-05-07 2022-07-15 江苏艾立康医药科技有限公司 一种替格瑞洛控释片及其制备方法
GB2613900B (en) * 2021-12-20 2024-01-17 Cereno Scient Ab Novel compounds and methods of use thereof
WO2026068561A1 (en) 2024-09-24 2026-04-02 Cereno Scientific Ab Valproic acid for use in treating pulmonary arterial hypertension

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4356108A (en) 1979-12-20 1982-10-26 The Mead Corporation Encapsulation process
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
ATE68346T1 (de) 1987-07-22 1991-11-15 Farvalsa Ag Feuchtigkeitsstabile feste valproinsaeurezubereitung und verfahren zu ihrer herstellung.
SE9402422D0 (sv) 1994-07-08 1994-07-08 Astra Ab New beads for controlled release and a pharmaceutical preparation containing the same
SE9402431D0 (sv) 1994-07-08 1994-07-08 Astra Ab New tablet formulation
US6713086B2 (en) * 1998-12-18 2004-03-30 Abbott Laboratories Controlled release formulation of divalproex sodium
CN1228043C (zh) 1999-09-30 2005-11-23 爱德华·孟岱尔股份有限公司 用于高溶解度药物的缓释基质
AT408718B (de) 1999-12-02 2002-02-25 Gerot Pharmazeutika Natriumvalproat-granulat mit verringerter hygroskopizität
AU2002243231A1 (en) 2000-11-21 2002-07-24 Wake Forest University Method of treating autoimmune diseases
ITMI20011733A1 (it) 2001-08-07 2003-02-07 Italfarmaco Spa Derivati dell'acido idrossamico inibitori degli enzimi istone deacetilasi, quali nuovi farmaci antiinfiammatori inibenti la sintesi di citoc
US7090858B2 (en) 2001-08-09 2006-08-15 Swaminathan Jayaraman Coated filter bag material for oral administration of medicament in liquid and methods of making same
JP2006507297A (ja) * 2002-05-13 2006-03-02 チルドレンズ・ホスピタル・ロサンジェルス ケロイドおよび他の皮膚または内部創傷または病変における異常瘢痕形成の処置および予防
US8034831B2 (en) 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
US20040224006A1 (en) * 2003-04-21 2004-11-11 Samn Raffaniello Ancrod irradiated, impregnated or coated sutures and other first aid or wound management bandaging materials for minimizing scarring and/or preventing excessive scar formation
ITMI20040876A1 (it) 2004-04-30 2004-07-30 Univ Degli Studi Milano Inibitori delle istone deacetilasi-hdac-quali agenti ipolipidemizzati per la terapia e la prevenzione dell'arteriosclerosi e malattie cardiovascolari
DK1591109T3 (da) 2004-04-30 2008-10-06 Topotarget Germany Ag Formulering, der omfatter histondeacetylaseinhibitorer, der udviser tofaset frigivelse
US7713550B2 (en) * 2004-06-15 2010-05-11 Andrx Corporation Controlled release sodium valproate formulation
US20050276848A1 (en) 2004-06-15 2005-12-15 Nilobon Podhipleux Sustained release neutralized divalproex sodium
WO2006117165A2 (en) 2005-05-02 2006-11-09 Friedrich-Alexander-Universität Erlangen-Nürnberg Means and methods for the treatment of head injuries and stroke
EP1743654A1 (en) 2005-07-15 2007-01-17 TopoTarget Germany AG Use of inhibitors of histone deacetylases in combination with NSAID for the therapy of cancer and/or inflammatory diseases
EP1937236A2 (en) 2005-09-07 2008-07-02 Braincells, Inc. Modulation of neurogenesis by hdac inhibition
TWI393708B (zh) 2005-09-08 2013-04-21 Mei Pharma Inc 異羥肟酸脂化合物，其用途及其之合成方法
DE602006003848D1 (de) 2006-01-11 2009-01-08 Teva Pharma Formulierung zur verzögerten Freisetzung von Valproinsäure und deren Derivate
WO2007084775A2 (en) 2006-01-20 2007-07-26 The Trustees Of The University Of Pennsylvania Compositions and methods for modulation of suppressor t cell activation
US20090312311A1 (en) 2006-04-06 2009-12-17 Gary Michael Ksander Combination of organic compounds
US20080069878A1 (en) 2006-08-31 2008-03-20 Gopi Venkatesh Drug Delivery Systems Comprising Solid Solutions of Weakly Basic Drugs
GB2454118B (en) 2007-06-06 2010-06-02 Univ Maryland Hdac inhibitors and hormone targeted drugs for the treatment of cancer
US20090270497A1 (en) 2008-04-24 2009-10-29 Pharmacyclics, Inc. Treatment of Non-Localized Inflammation with pan-HDAC Inhibitors
GB201003766D0 (en) * 2010-03-05 2010-04-21 Univ Strathclyde Pulsatile drug release
WO2011113013A2 (en) 2010-03-11 2011-09-15 Hemaquest Pharmaceuticals, Inc. Methods and compositions for treating viral or virally-induced conditions
CN101947209B (zh) 2010-07-21 2012-07-25 河南中帅医药科技发展有限公司 双丙戊酸钠小丸及其制备方法
DK2683371T3 (da) * 2011-03-09 2021-01-18 Cereno Scient Ab Forbindelser og fremgangsmåder til forbedring af forringet endogen fibrinolyse ved anvendelse af histondeacetylasehæmmere
JP6330118B2 (ja) 2011-09-13 2018-05-30 ファーマサイクリックス エルエルシー ベンダムスチンと組み合わせたヒストンデアセチラーゼ阻害剤の製剤とその使用
GB201417828D0 (en) 2014-10-08 2014-11-19 Cereno Scient Ab New methods and compositions
CA3018043A1 (en) 2016-04-08 2017-10-12 Cereno Scientific Ab Delayed release pharmaceutical formulations comprising valproic acid, and uses thereof
WO2017175010A1 (en) 2016-04-08 2017-10-12 Cereno Scientific Ab Compounds and compositions for the treatment or prevention of pathological conditions associated with excess fibrin deposition and/or thrombus formation

Also Published As

Publication number Publication date
DK3203997T3 (da) 2022-05-23
RU2017114933A (ru) 2018-11-12
GB201417828D0 (en) 2014-11-19
US12245999B2 (en) 2025-03-11
PL3203997T3 (pl) 2022-05-16
AU2015329795B2 (en) 2021-03-25
CA3234641A1 (en) 2016-04-14
JP7305605B2 (ja) 2023-07-10
CN115721635A (zh) 2023-03-03
US20180177751A1 (en) 2018-06-28
CA2964041C (en) 2024-04-09
CN115581691A (zh) 2023-01-10
US10111845B2 (en) 2018-10-30
AU2015329795A1 (en) 2017-04-13
HUE058316T2 (hu) 2022-07-28
ES2913225T3 (es) 2022-06-01
EP4066825A1 (en) 2022-10-05
US20220401393A1 (en) 2022-12-22
IL251142A0 (en) 2017-04-30
CA2964041A1 (en) 2016-04-14
KR20170063857A (ko) 2017-06-08
BR112017007144A2 (pt) 2017-12-19
RU2732761C2 (ru) 2020-09-22
NZ730307A (en) 2024-01-26
WO2016055797A2 (en) 2016-04-14
MX2022007221A (es) 2022-07-12
EP3203997B1 (en) 2022-03-02
US20190015360A1 (en) 2019-01-17
IL251142B (en) 2022-07-01
JP6787901B2 (ja) 2020-11-18
RU2017114933A3 (es) 2019-05-16
EP3203997A2 (en) 2017-08-16
WO2016055797A3 (en) 2016-06-09
CN107205975A (zh) 2017-09-26
MY192055A (en) 2022-07-25
KR20250005512A (ko) 2025-01-09
JP2021008523A (ja) 2021-01-28
JP2017532376A (ja) 2017-11-02
SG11201702058XA (en) 2017-04-27
US20250241880A1 (en) 2025-07-31
MX2017004558A (es) 2017-12-14
US11400064B2 (en) 2022-08-02

Similar Documents

Publication Publication Date Title
CL2017000866A1 (es) Compuestos y composiciones para el tratamiento o prevencion de trastornos patologicos asociados con exceso de deposicion de fibrina y/o formacion de trombos
PH12017500583A1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
PH12016501457A1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
MX2018006223A (es) Moduladores de ror-gamma.
ECSP17013903A (es) Protein kinase c inhibitors and methods of their use
EA201691582A1 (ru) Новые фармацевтические препараты
EA201591743A8 (ru) СТИМУЛЯТОРЫ sGC
CR20150078A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
WO2014179564A8 (en) Thiazolopyrrolidine inhibitors of ror-gamma
EA201600589A1 (ru) Ингибиторы диацилглицеринацилтрансферазы 2 для применения в лечении метаболических и связанных с метаболизмом расстройств
MX389591B (es) INHIBIDORES DE ACIDO A-AMINO-ß-CARBOXIMUCONICO SEMIALDEHIDO DESCARBOXILASA
MX2016011105A (es) Inhibidores de monoacilglicerol aciltransferasa 2 (mgat2) de dihidropiridinona para usarse en el tratamiento de trastornos metabolicos.
PH12016502530A1 (en) Pharmaceutical compositions comprising dgla and use of same
EA201790315A1 (ru) Модуляторы x-рецепторов печени
MX2017001855A (es) Compuestos biciclicos sustituidos.
EA201790830A1 (ru) Ингибиторы альдостеронсинтазы
MX2018005004A (es) Compuestos de indazol substituidos como inhibidores de rorgammat y sus usos.
EA201692020A1 (ru) Пролекарственные средства янтарной кислоты для применения в лечении лактоацидоза или индуцируемого лекарственными средствами побочного действия вследствие связанных с комплексом i нарушений окислительного фосфорилирования в митохондриях
MX2017013103A (es) Metodos para el tratamiento de trastornos cardiovasculares.
MX2016013451A (es) Heterociclilsulfonas arilo sustituidas.
EA201790020A1 (ru) Соединения, фармацевтические композиции и их применение при лечении нейродегенеративных заболеваний
EA201890911A1 (ru) Комбинация тразодона и габапентина для лечения боли
ES2721003T3 (es) Utilización de ácido 1, 3 - propano disulfónico o sales farmacéuticamente aceptables del mismo para el tratamiento de la sarcoidosis
RU2014154366A (ru) Применение пробиотического штамма микроорганизма enterococcus faecium l3 для лечения нейродегенеративных заболеваний
CL2015001705A1 (es) Uso de pidotimod para tratar la psoriasis